Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis - (2022)
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS - (2022)
CBMR joins €2M Horizon2020 project to help steer the future of human microbiome research
The Human Microbiome Action consortium will bring more than [...]
Human Microbiome Action at MicrobiomeSupport Final Conference
Between the 27th and 29th of June 2022, the [...]
The European CSA Human Microbiome Action (2021-2024)
Human Microbiome Action at the ONE – Health, Environment, Society – Conference 2022.
“Love is a microbe too”: Microbiome dialectics
“Love is a microbe too”: Microbiome dialectics - (2022)
1st Annual Meeting – Salerno, Italy
On May 10th, the Human Microbiome Action consortium hold [...]
Modeling microbiota-associated human diseases: from minimal models to complex systems
Modeling microbiota-associated human diseases: from minimal models to complex systems - (2022)
Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments - (2022)
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders - (2022)
